Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
232.61
+18.17 (8.47%)
NASDAQ · Last Trade: Nov 3rd, 10:55 AM EST
News & Press Releases
JAZZ Q3 deep dive: oncology momentum and new launches offset margin pressure
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) beat Wall Street’s revenue expectations in Q3 2026, with sales up 10.4% year on year to $1.24 billion. T...
Via StockStory · November 3, 2026
Jazz (JAZZ) Q3 2026 Earnings Call Transcriptfool.com
Oncology portfolio surges 35% as Ziihera launches and Xywav sustains momentum.
Via The Motley Fool · November 2, 2026
Jazz Pharmaceuticals Q3 Earnings Call Highlightsmarketbeat.com
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported record third-quarter revenue of $1.24 billion, up 10% from a year earlier, and raised its full-year 2026 revenue outlook as growth in its sleep and oncology businesses offset product-specific pressures and continued investment in its pipeline.
Chief Execu
Via MarketBeat · November 2, 2026
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q3 Results In Line as Raised Guidance Sparks After-Hours Surgechartmill.com
Via Chartmill · November 2, 2026
Cannabis Stocks’ Rally Is Narrow as Profitable Healthcare and Consumer Names Do the Heavy Liftingchartmill.com
Via Chartmill · October 22, 2026
Jazz Pharmaceuticals (NASDAQ:JAZZ): An Undervalued Biopharma Value Stockchartmill.com
Via Chartmill · October 9, 2026
Cannabis Stocks Aren’t a Recovery Trade: Narrow Leadership Splits Quality and Momentumchartmill.com
Via Chartmill · October 6, 2026
Jazz Pharmaceuticals (NASDAQ:JAZZ) surprises with Q3 2026 sales, full-year sales guidance is optimistic
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) beat Wall Street’s revenue expectations in Q3 2026, with revenue rising 10.4% year on year to $1.24 bill...
Via StockStory · November 2, 2026
What to expect from Jazz Pharmaceuticals’s (JAZZ) Q3 earnings
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting results this Monday after market hours. Here’s what to expect. Jazz Pharmaceuticals be...
Via StockStory · October 31, 2026
Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth Enginefool.com
Jazz Pharmaceuticals' strategy is starting to pay dividends.
Via The Motley Fool · October 27, 2026
3 Healthcare Stocks That Concern Us
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...
Via StockStory · October 16, 2026
Cannabis Stocks: A Profitability Turnaround Is Brewing Beneath Weak Price Actionchartmill.com
Via Chartmill · September 22, 2026
Jazz Pharmaceuticals (NASDAQ:JAZZ): A Decent Value Stock Trading Below Its Worthchartmill.com
Via Chartmill · September 2, 2026
Cannabis Rally Turns Selective as Investors Reward Pharma-Tinged Nameschartmill.com
Via Chartmill · August 29, 2026
3 of Wall Street’s Favorite Stocks That Fall Short
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
Via StockStory · October 14, 2026
Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NAS...
Via StockStory · September 29, 2026
Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1Bmarketbeat.com
Jazz Pharmaceuticals (NASDAQ:JAZZ) executives outlined the company’s oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Global Healthcare Conference.
Chumi Khurana, senior vice president of U.S. Oncology
Via MarketBeat · September 20, 2026
Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expandsmarketbeat.com
Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX.
Zii
Via MarketBeat · September 20, 2026
Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?fool.com
Actio could make Jazz's growing epilepsy franchise even stronger.
Via The Motley Fool · September 18, 2026
3 Cash-Producing Stocks We’re Skeptical Of
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Via StockStory · September 11, 2026
2 Reasons to Avoid JAZZ and 1 Stock to Buy Instead
Jazz Pharmaceuticals’s 29.7% return over the past six months has outpaced the S&P 500 by 17%, and its stock price has climbed to $240.49 per share. This was ...
Via StockStory · September 11, 2026
1 Value Stock with Exciting Potential and 2 We Brush Off
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t...
Via StockStory · September 8, 2026
Stocks making big moves yesterday: Jazz Pharmaceuticals, SAIC, Herbalife, AGCO, and Deere
Check out the companies making headlines yesterday: Jazz Pharmaceuticals (NASDAQ:JAZZ): Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) rose by 2.5% on ...
Via StockStory · September 1, 2026
Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why
What Happened? Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 2.5% in the afternoon session after the company announced positive Phase...
Via StockStory · August 31, 2026
Jazz Pharmaceuticals Launches Ziihera After FDA Nod in HER2-Positive GEAmarketbeat.com
Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined its plans for the U.S. launch of Ziihera following FDA approval of the therapy for first-line HER2-positive unresectable, locally advanced or metastatic gastroesophageal adenocarcinoma, or GEA.
Ziihera, or zanidatamab, is approved in combination with tisl
Via MarketBeat · August 25, 2026